From each FDA label

Do GLP-1s cause bone loss?

No current GLP-1 label prints a rate for bone loss in its main trial table.

Read from each manufacturer's FDA label on DailyMed. The newest revision saying anything on this is Jun 18, 2026.

Word for word

What each label says about bone loss

Sentences from each label's warnings and side effect sections. Only cross-references are removed.

Wegovy

  • In the CV outcomes trial in adults, more fractures of the hip and pelvis were reported on Wegovy than on placebo in female patients: 1% (24/2,448) vs. 0.2% (5/2,424), and in patients ages 75 years and older: 2.4% (17/703) vs. 0.6% (4/663), respectively.
  • In a clinical trial in adults with MASH, fractures occurred in 4.4% of Wegovy-treated patients (2.6 cases per 100 patient years) compared to 3.3% of placebo-treated patients (2 cases per 100 patient years).
  • Fractures were reported in both males and females with a median age of 61 years (range, 44 to 75).

Label revised Jun 18, 2026. DailyMed

Ozempic, Rybelsus and Ozempic tablets, Zepbound, Mounjaro, Foundayo, Trulicity, Saxenda, Victoza, Byetta: no finding on this in the sections read here.

Not from trials

Reports to FDA about bone loss

Counts of voluntary reports from patients and doctors. They cannot show that a medicine caused anything and cannot give a rate, and a brand used by more people draws more reports.

MedicineReports namingAll reports on it
OzempicOsteoporosis: 66 · Osteopenia: 27 · Fracture: 2370,863
VictozaOsteoporosis: 46 · Bone density decreased: 16 · Osteopenia: 1241,462
TrulicityOsteoporosis: 34 · Fracture: 29 · Bone density decreased: 2087,279
ByettaOsteoporosis: 30 · Osteopenia: 2252,087
MounjaroFracture: 23 · Osteoporosis: 22 · Osteopenia: 1497,440
WegovyOsteoporosis: 15 · Osteopenia: 12 · Fracture: 1125,993
ZepboundOsteoporosis: 11 · Osteopenia: 6 · Bone density decreased: 580,835
Rybelsus and Ozempic tabletsFracture: 10 · Osteoporosis: 5 · Bone density decreased: 37,758
SaxendaOsteoporosis: 9 · Bone density decreased: 27,270

Counted through openFDA from FDA's Adverse Event Reporting System, refreshed weekly. One report can name several terms.

Updated automatically

Latest FDA label updates

Written from each source's own record as it changes. Every change on GLPcompare

Questions

Bone loss on a GLP-1: common questions

Does Wegovy cause bone loss?

Its FDA label: In the CV outcomes trial in adults, more fractures of the hip and pelvis were reported on Wegovy than on placebo in female patients: 1% (24/2,448) vs. 0.2% (5/2,424), and in patients ages 75 years and older: 2.4% (17/703) vs. 0.6% (4/663), respectively. In a clinical trial in adults with MASH, fractures occurred in 4.4% of Wegovy-treated patients (2.6 cases per 100 patient years) compared to 3.3% of placebo-treated patients (2 cases per 100 patient years).

Other side effects

Trial rates describe groups, not what one person will feel. Talk to your clinician before starting, stopping or changing a medicine.

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.